POSTED: January 22, 2013

In an exciting breakthrough, scientists at UCLA’s Jonsson Comprehensive Cancer Center recently reported an encouraging increase in progression-free survival (or PFS, the length of time a patient is on treatment without tumor growth) for patients with HER2-negative breast cancer, a particularly aggressive form of the disease. In this informative video, lead researcher Dr. Richard Finn explains the positive results of this pioneering study and the possibilities it opens up for future breast cancer treatments.